Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Acquisitions & Divestments (2018 - 2021)

Iradimed (IRMD) reported Change in Acquisitions & Divestments of $440000.0 for Q4 2021, up 8.99% year-over-year from $403715.0 in Q4 2020, and up 8.99% on a QoQ basis from $403715.0 in Q4 2020.

Iradimed (IRMD) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $440000.0 in Q4 2021.

  • Quarterly Change in Acquisitions & Divestments rose 8.99% year-over-year to $440000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2022 was $440000.0 (down 47.85% YoY) and the FY2022 annual result came in at $500000.0, down 64.03% from the prior year.
  • Change in Acquisitions & Divestments rose to $440000.0 in Q4 2021 per IRMD's latest filing, from $403715.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.5 million in Q3 2019 and bottomed at $400000.0 in Q2 2019.
  • The 4-year median for Change in Acquisitions & Divestments is $775000.0 (2018), against an average of $825714.4.
  • The widest annual swing landed in 2019, when Change in Acquisitions & Divestments soared 63.56%; it then sank 65.35% in 2020.
  • Tracing IRMD's Change in Acquisitions & Divestments over 4 years: stood at $1.2 million in 2018, then declined by 0.85% to $1.2 million in 2019, then slumped by 65.35% to $403715.0 in 2020, then gained by 8.99% to $440000.0 in 2021.
  • Per Business Quant, the three latest IRMD Change in Acquisitions & Divestments figures stand at $440000.0 (Q4 2021), $403715.0 (Q4 2020), and $1.2 million (Q4 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Iradimed 1.17 Bn 1.11 Bn 16.81 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 440,000.00
Dec 31, 2021 440,000.00
Dec 31, 2020 403,715.00
Dec 31, 2020 403,715.00
Dec 31, 2019 1.17 Mn
Dec 31, 2019 1.17 Mn
Sep 30, 2019 1.47 Mn
Sep 30, 2019 1.47 Mn
Jun 30, 2019 400,000.00
Jun 30, 2019 400,000.00
Mar 31, 2019 650,000.00
Mar 31, 2019 650,000.00
Dec 31, 2018 1.18 Mn
Dec 31, 2018 1.18 Mn
Sep 30, 2018 900,000.00
Sep 30, 2018 900,000.00